Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02033317 · ClinicalTrials.gov registry record · Phase 2
An Open-Label, Multiple Dose Study to Evaluate the Pharmacology, Safety, and Tolerability of Patiromer in Participants on Hemodialysis
A Phase 2 study, sponsored by Relypsa.
- Terminated
- Registry status
- Phase 2
- Development phase
- 6
- Enrollment target
NCT02033317 is a Phase 2 study that was terminated before completion, run by Relypsa. The registered enrollment target is 6 participants.
The verdict
NCT02033317, a Phase 2 study, was terminated before completion, sponsored by Relypsa.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 6 participants
- Enrollment target
Study Summary
This study assessed the pharmacodynamic effects of patiromer on serum potassium in participants on hemodialysis.
Interventions
- DRUG patiromer
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6 participants |
| Start Date | 2008-08 |
| Est. Completion | 2008-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02033317
The ClinicalTrials.gov registry entry for NCT02033317 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 6 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Relypsa, which has 5 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which patiromer is the first listed.
NCT02033317 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02033317 about?
NCT02033317 is a clinical study titled "An Open-Label, Multiple Dose Study to Evaluate the Pharmacology, Safety, and Tolerability of Patiromer in Participants on Hemodialysis". This study assessed the pharmacodynamic effects of patiromer on serum potassium in participants on hemodialysis.
What is the current status of trial NCT02033317?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 6 participants. The study started on 2008-08. Estimated completion is 2008-12.
What interventions are being tested in trial NCT02033317?
The interventions under investigation include: patiromer (DRUG).
Who is sponsoring clinical trial NCT02033317?
This trial is sponsored by Relypsa, which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.